Galectin Therapeutics Inc. (GALT)
| Market Cap | 152.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.97M |
| Shares Out | 65.83M |
| EPS (ttm) | -0.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137,956 |
| Open | 2.340 |
| Previous Close | 2.370 |
| Day's Range | 2.305 - 2.390 |
| 52-Week Range | 1.210 - 7.130 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+266.38%) |
| Earnings Date | May 14, 2026 |
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Ther... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GALT stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 266.38% from the latest price.
News
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., (“Galectin" or the "Company") (NASDAQ: GALT) investors that the firm has initiated an investig...
Galectin Therapeutics Transcript: KOL event
Belapectin demonstrated significant reduction in new esophageal varices and improvement in key fibrosis biomarkers in advanced MASH cirrhosis patients with portal hypertension. The therapy showed a strong safety profile and is uniquely positioned to address an unmet need, with regulatory discussions ongoing.
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeu...
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $GALT--GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm.
Galectin Therapeutics Transcript: AGM 2025
The meeting saw the re-election of all directors, approval of executive compensation, and ratification of the auditor. Key updates included strong Navigate trial results for belapectin, ongoing FDA engagement, and strategic planning for future growth.
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p...
Galectin Therapeutics Transcript: H.C. Wainwright Liver Disease Virtual Conference
Presenters detailed promising results for belapectin in preventing varices and reducing fibrosis in MASH cirrhosis with portal hypertension, highlighting its favorable safety profile and potential as a first-in-class therapy. Regulatory and partnership discussions are ongoing.
Galectin Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Belapectin demonstrated a significant reduction in varices incidence in NASH cirrhosis patients with portal hypertension, especially in those completing the full protocol, and showed favorable biomarker and safety profiles. Regulatory discussions and partnership opportunities are underway.
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company mana...
Galectin Therapeutics Transcript: Study Result
Belapectin demonstrated a significant reduction in new esophageal varices and disease progression in advanced MASH cirrhosis patients with portal hypertension, especially in those without baseline varices, and showed a favorable safety profile. NAVIGATE results validate earlier findings and highlight a major market opportunity.
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hyperte...
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line resu...
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirr...
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its globa...
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of th...
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p...
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts f...
Galectin Therapeutics Transcript: 9th Annual MASH Investor Conference
Belapectin, a galectin-3 inhibitor, is advancing through pivotal trials for MASH cirrhosis and oncology, with promising safety and efficacy data. The NAVIGATE trial's interim results in Q4 could position it as the first FDA-approved therapy for cirrhosis with portal hypertension.
Galectin Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
Belapectin, a galectin-3 inhibitor, is advancing in late-stage trials for NASH cirrhosis and portal hypertension, with promising efficacy and safety data, and a novel, FDA-endorsed clinical endpoint. The program targets a vast unmet need and multi-billion dollar market.
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chie...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khu...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and pr...